Cancer, CNS & Cardiovascular Biomarkers · Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects. ii ©Espicom Business Intelligence August 2008 Cancer, CNS & Cardiovascular

World Leaders in Health Industry Analysis

Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects

©Espicom Business Intelligence August 2008ii

Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects

August 2008

ISBN: 978-1-85822-327-8

© Copyright 2008 Espicom Business Intelligence

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of

the publisher.

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained herein.

British Library Cataloguing in Publication Data.

A catalogue record for this report is available from the British Library.

©Espicom Business Intelligence iiiAugust 2008

Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects Table of Contents

ContentsEXECUTIVE SUMMARY .................................................................................................................................. 1

Figure1: Growth in biomarker market 2007-2015 .................................................................................................................................................................................1What are biomarkers? ...........................................................................................................................................................2Why are they important? ......................................................................................................................................................2

Figure 2: Potential impact of biomarkers on disease pathways ............................................................................................................................................................2What technologies are involved? .........................................................................................................................................3What impact will biomarkers have on R&D? .......................................................................................................................3

Figure 3: Potential impact of biomarkers on R&D ..................................................................................................................................................................................3Who are the major biomarker players and in what research area? ..................................................................................4Cancer biomarker companies ..............................................................................................................................................5Cardiovascular biomarker companies .................................................................................................................................6CNS biomarkers companies ..................................................................................................................................................7Company Analysis Criteria ....................................................................................................................................................7

Biomarker technology & platforms ................................................................................................................................................7Association/clinical studies ..............................................................................................................................................................8Management strategy ......................................................................................................................................................................8Application & potential .....................................................................................................................................................................8

CANCER MARKET & REVENUES .................................................................................................................... 9Market revenues - global ......................................................................................................................................................9

Figure 1: Global cancer drugs sales (2007) .............................................................................................................................................................................................9Market revenues – leading brands ....................................................................................................................................10

Figure 2: Leading cancer brands (2007) ...............................................................................................................................................................................................10Market revenues – leading players ....................................................................................................................................11

Figure 3: Top 10 oncology players (2007 revenues) .............................................................................................................................................................................11CANCER EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT ................................................................................ 12

Epidemiology .......................................................................................................................................................................12Table 1: Cancer Statistics for four most common cancers, 2008 ..........................................................................................................................................................12

Diagnosis ..............................................................................................................................................................................12Screening .............................................................................................................................................................................13

Table 2: Cancer screening .....................................................................................................................................................................................................................13Current & future treatment ................................................................................................................................................14Future treatment .................................................................................................................................................................14

Figure 4: Anticancer drugs in clinical development..............................................................................................................................................................................15CANCER BIOMARKERS ........................................................................................................................................................... 16

Cancer biomarker R&D ........................................................................................................................................................16Table 3: Types of biomarker ..................................................................................................................................................................................................................17

Known cancer biomarkers ..................................................................................................................................................17Table 4: Commercially available known cancer biomarker diagnostics ..............................................................................................................................................17

Probable and possible valid cancer biomarkers ..............................................................................................................18Table 5: Probable cancer biomarkers diagnostics ................................................................................................................................................................................19Table 6: Possible cancer biomarkers diagnostics ..................................................................................................................................................................................19

CANCER BIOMARKER OPPORTUNITIES & CHALLENGES ................................................................................................... 21Opportunities ......................................................................................................................................................................21Challenges ............................................................................................................................................................................21

BIOMARKER MARKET .............................................................................................................................................................23Biomarker market revenues - global ................................................................................................................................ 23

Figure 8: Global biomarker sales in 2007 .............................................................................................................................................................................................23Cancer biomarker market revenues - global ................................................................................................................... 24

Figure 9: Global cancer biomarker sales in 2007 .................................................................................................................................................................................24

©Espicom Business Intelligence August 2008iv

Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospectsSection Name

Future biomarker market revenues – global ................................................................................................................... 24Figure 10: Global biomarker sales in 2015 ...........................................................................................................................................................................................25

Future cancer biomarker market revenues - global ........................................................................................................ 25Figure 11: Global cancer biomarker sales in 2015 ................................................................................................................................................................................26

CANCER BIOMARKER TRENDS .............................................................................................................................................. 27Table 7: Recent deals in oncology biomarkers ......................................................................................................................................................................................27

Pharma and specialty pharma deals ................................................................................................................................ 29Collaborations with service providers ............................................................................................................................. 29Collaborations with academics and consortia ................................................................................................................ 29

BIOMARKER ANALYSIS ...........................................................................................................................................................30DNA biomarkers ................................................................................................................................................................. 30RNA and microRNA biomarkers ........................................................................................................................................ 30Proteomic biomarkers ....................................................................................................................................................... 30

KEY BIOMARKER COMPANIES ANALYSED ........................................................................................................................... 31KEY BIOMARKER EVALUATION CRITERIA ............................................................................................................................ 32

CANCER BIOMARKER- COMPANY ANALYSIS ............................................................................................. 33Abbott Diagnostics ................................................................................................................................................................. 33

Biomarker novelty & technology platform .......................................................................................................................33Figure 12: Abbott’s UroVysion bladder cancer test ...............................................................................................................................................................................33

Association studies/clinical data ....................................................................................................................................... 34Pivotal Trial ........................................................................................................................................................................................34Table 7: Comparison of UroVysion vs Cystoscopy/Histology for Detection of Bladder Cancer Recurrence by Stage and Grade* .........................................................34

Management strategy ....................................................................................................................................................... 34Application & market potential ........................................................................................................................................ 34Biomarker analysis ..............................................................................................................................................................35

Affymetrix ................................................................................................................................................................................ 36Biomarker novelty & technology platform ...................................................................................................................... 36

Figure 13: Affymetrix’ approach to biomarker discovery, validation and clinical utility applications .................................................................................................36Association studies/clinical data ........................................................................................................................................37Management strategy ........................................................................................................................................................37Application & market potential .........................................................................................................................................37Biomarker analysis ..............................................................................................................................................................37

Agendia BV............................................................................................................................................................................... 39Biomarker novelty & technology platform ...................................................................................................................... 39Association studies/clinical data ....................................................................................................................................... 39

Figure 14: MammaPrint Profile vs NIH Consensus Criteria ...................................................................................................................................................................39Management strategy ....................................................................................................................................................... 40Application & market potential ........................................................................................................................................ 40Biomarker analysis ............................................................................................................................................................. 40

AltheaDx ................................................................................................................................................................................... 41Biomarker novelty & technology platform .......................................................................................................................41Association studies/clinical data ........................................................................................................................................41Management strategy ........................................................................................................................................................41Application & market potential .........................................................................................................................................41Biomarker analysis ..............................................................................................................................................................41

AVEO Pharmaceuticals ........................................................................................................................................................... 43Biomarker novelty & technology platform ...................................................................................................................... 43Association studies/clinical data ....................................................................................................................................... 43Management strategy ....................................................................................................................................................... 43Application & market potential ........................................................................................................................................ 43Biomarker analysis ............................................................................................................................................................. 44

©Espicom Business Intelligence vAugust 2008

Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects Section Name

AviaraDx ................................................................................................................................................................................... 45Biomarker novelty & technology platform ...................................................................................................................... 45Association studies/clinical data ....................................................................................................................................... 45Management strategy ....................................................................................................................................................... 45Application & market potential ........................................................................................................................................ 46Biomarker analysis ............................................................................................................................................................. 46

BG Medicine ............................................................................................................................................................................. 47Biomarker novelty & technology platform .......................................................................................................................47Association studies/clinical data ........................................................................................................................................47Management strategy ........................................................................................................................................................47

Figure 15: BG Medicines Biomarker Programme .................................................................................................................................................................................48Application & market potential ........................................................................................................................................ 48Biomarker analysis ............................................................................................................................................................. 48

Beckman Coulter ....................................................................................................................................................................50Biomarker novelty & technology platform ...................................................................................................................... 50Association studies/clinical data ....................................................................................................................................... 50Management strategy ....................................................................................................................................................... 50Application & market potential .........................................................................................................................................51Biomarker analysis ..............................................................................................................................................................51

BioCurex ................................................................................................................................................................................... 52Biomarker novelty & technology platform .......................................................................................................................52Association studies/clinical data ........................................................................................................................................52Management strategy ........................................................................................................................................................52Application & market potential .........................................................................................................................................53Biomarker analysis ..............................................................................................................................................................53

Biomedical Diagnostics .........................................................................................................................................................54Biomarker novelty & technology platform ...................................................................................................................... 54Association studies/clinical data ....................................................................................................................................... 54Management strategy ....................................................................................................................................................... 54Application & market potential ........................................................................................................................................ 54Biomarker analysis ..............................................................................................................................................................55

Biomerica .................................................................................................................................................................................56Biomarker novelty & technology platform ...................................................................................................................... 56Association studies/clinical data ....................................................................................................................................... 56Management strategy ....................................................................................................................................................... 56Application & market potential ........................................................................................................................................ 56Biomarker analysis ..............................................................................................................................................................57

Bruker Daltonics ......................................................................................................................................................................58Biomarker novelty & technology platform ...................................................................................................................... 58Association studies/clinical data ....................................................................................................................................... 58Management strategy ....................................................................................................................................................... 58Application & market potential ........................................................................................................................................ 58Biomarker analysis ............................................................................................................................................................. 58

Caprion Proteomics ................................................................................................................................................................60Biomarker novelty & technology platform ...................................................................................................................... 60Association studies/clinical data ....................................................................................................................................... 60Management strategy ....................................................................................................................................................... 60Application & market potential ........................................................................................................................................ 60Biomarker analysis ............................................................................................................................................................. 60

Clinical Data ............................................................................................................................................................................. 62Biomarker novelty & technology platform ...................................................................................................................... 62

©Espicom Business Intelligence August 2008vi


Association studies/clinical data ....................................................................................................................................... 62Management strategy ....................................................................................................................................................... 62Application & market potential ........................................................................................................................................ 62Biomarker analysis ............................................................................................................................................................. 63

Celera ........................................................................................................................................................................................64Biomarker novelty & technology platform ...................................................................................................................... 64Association studies/clinical data ....................................................................................................................................... 64Management strategy ....................................................................................................................................................... 64Application & market potential ........................................................................................................................................ 65Biomarker analysis ............................................................................................................................................................. 65

Dako Denmark A/S .................................................................................................................................................................66Biomarker novelty & technology platform ...................................................................................................................... 66Association studies/clinical data ....................................................................................................................................... 66Management strategy ....................................................................................................................................................... 66Application & market potential ........................................................................................................................................ 66Biomarker analysis ..............................................................................................................................................................67

DxS Ltd ......................................................................................................................................................................................68Biomarker novelty & technology platform ...................................................................................................................... 68Association studies/clinical data ....................................................................................................................................... 68Management strategy ....................................................................................................................................................... 68Application & market potential ........................................................................................................................................ 68Biomarker analysis ............................................................................................................................................................. 69

Epigenomics AG ...................................................................................................................................................................... 70Biomarker novelty & technology platform .......................................................................................................................70Association studies/clinical data ........................................................................................................................................70Management strategy .......................................................................................................................................................70Application & market potential .........................................................................................................................................71Biomarker analysis ..............................................................................................................................................................71

Epistem Plc ............................................................................................................................................................................... 72Biomarker novelty & technology platform ...................................................................................................................... 72

Figure 16: Epistem’s Biomarker Drug Development Programme ........................................................................................................................................................72Association studies/clinical data ....................................................................................................................................... 73Management strategy ....................................................................................................................................................... 73Application & market potential ........................................................................................................................................ 73Biomarker analysis ............................................................................................................................................................. 73

GeneNews ................................................................................................................................................................................ 75Biomarker novelty & technology platform .......................................................................................................................75

Figure 17: GeneNews’ Sentinel Principle ..............................................................................................................................................................................................75Association studies/clinical data ........................................................................................................................................76Management strategy ........................................................................................................................................................76Application & market potential .........................................................................................................................................76Biomarker analysis ..............................................................................................................................................................76

Fujirebio Diagnostics, Inc ...................................................................................................................................................... 78Biomarker novelty & technology platform ...................................................................................................................... 78Association studies/clinical data ....................................................................................................................................... 78Management strategy ....................................................................................................................................................... 78Application & market potential ........................................................................................................................................ 79Biomarker analysis ............................................................................................................................................................. 79

Genomic Health ......................................................................................................................................................................80Biomarker novelty & technology platform ...................................................................................................................... 80

Figure 18: Oncotype Dx test for invasive breast cancer ........................................................................................................................................................................80

©Espicom Business Intelligence viiAugust 2008


Association studies/clinical data ....................................................................................................................................... 80Management strategy ........................................................................................................................................................81Application & market potential .........................................................................................................................................81Biomarker analysis ..............................................................................................................................................................81

Gen-Probe ................................................................................................................................................................................ 83Biomarker novelty & technology platform ...................................................................................................................... 83Association studies/clinical data ....................................................................................................................................... 83Management strategy ....................................................................................................................................................... 83Application & market potential ........................................................................................................................................ 84Biomarker analysis ............................................................................................................................................................. 84

Genzyme Genetics ..................................................................................................................................................................85Biomarker novelty & technology platform ...................................................................................................................... 85Association studies/clinical data ....................................................................................................................................... 85Management strategy ....................................................................................................................................................... 85Application & market potential ........................................................................................................................................ 85Biomarker analysis ............................................................................................................................................................. 86

InterGenetics ........................................................................................................................................................................... 87Biomarker novelty & technology platform ...................................................................................................................... 87Association studies/clinical data ....................................................................................................................................... 87Management strategy ....................................................................................................................................................... 87Application & market potential ........................................................................................................................................ 87Biomarker analysis ............................................................................................................................................................. 88

Ipsogen Therapeutics ...........................................................................................................................................................89Biomarker novelty & technology platform ...................................................................................................................... 89Association studies/clinical data ....................................................................................................................................... 89Management strategy ....................................................................................................................................................... 89

Figure 19: Oncotype Dx test for invasive breast cancer ........................................................................................................................................................................90Application & market potential ........................................................................................................................................ 90Biomarker analysis ............................................................................................................................................................. 90

Laboratory Corporation of America .................................................................................................................................... 91Biomarker novelty & technology platform .......................................................................................................................91Association studies/clinical data ........................................................................................................................................91Management strategy ........................................................................................................................................................91Application & market potential .........................................................................................................................................91Biomarker analysis ..............................................................................................................................................................91

Matritech .................................................................................................................................................................................. 93Biomarker novelty & technology platform ...................................................................................................................... 93Association studies/clinical data ....................................................................................................................................... 93Management strategy ....................................................................................................................................................... 93Application & market potential ........................................................................................................................................ 93Biomarker analysis ............................................................................................................................................................. 94

Monogram Biosciences ......................................................................................................................................................... 95Biomarker novelty & technology platform ...................................................................................................................... 95

Figure 20: VeraTag Assay ......................................................................................................................................................................................................................95Association studies/clinical data ....................................................................................................................................... 95

Figure 21: VeraTag Clinical Data: Bordet Cohort ...................................................................................................................................................................................96Management strategy ....................................................................................................................................................... 96Application & market potential ........................................................................................................................................ 96Biomarker analysis ............................................................................................................................................................. 97

Orion Genomics ......................................................................................................................................................................98Biomarker novelty & technology platform ...................................................................................................................... 98

©Espicom Business Intelligence August 2008viii


Figure 22: Orion’s MethylScope ............................................................................................................................................................................................................98Association studies/clinical data ....................................................................................................................................... 98Management strategy ....................................................................................................................................................... 99Application & market potential ........................................................................................................................................ 99Biomarker analysis ............................................................................................................................................................. 99

Oxford Genome Biosciences (UK) Ltd ...............................................................................................................................100Biomarker novelty & technology platform .................................................................................................................... 100Association studies/clinical data ..................................................................................................................................... 100Management strategy ..................................................................................................................................................... 100Application & market potential ...................................................................................................................................... 100Biomarker analysis ............................................................................................................................................................101

Power3 Medical Products ....................................................................................................................................................102Biomarker novelty & technology platform .................................................................................................................... 102Association studies/clinical data ..................................................................................................................................... 102Management strategy ..................................................................................................................................................... 102

Figure 23: Powder3’s business strategy ..............................................................................................................................................................................................103Application & market potential ...................................................................................................................................... 103Biomarker analysis ........................................................................................................................................................... 103

Predictive Biosciences .......................................................................................................................................................... 105Biomarker novelty & technology platform .................................................................................................................... 105Association studies/clinical data ..................................................................................................................................... 105Management strategy ..................................................................................................................................................... 105Application & market potential ...................................................................................................................................... 105Biomarker analysis ........................................................................................................................................................... 106

Provista Life Sciences ...........................................................................................................................................................107Biomarker novelty & technology platform .................................................................................................................... 107Association studies/clinical data ..................................................................................................................................... 107Management strategy ..................................................................................................................................................... 107Application & market potential ...................................................................................................................................... 108Biomarker analysis ........................................................................................................................................................... 108

Quest Diagnostics .................................................................................................................................................................109Biomarker novelty & technology platform .................................................................................................................... 109Association studies/clinical data ..................................................................................................................................... 109Management strategy ..................................................................................................................................................... 109Application & market potential ...................................................................................................................................... 109Biomarker analysis ............................................................................................................................................................110

Roche Diagnostics .................................................................................................................................................................111Biomarker novelty & technology platform .....................................................................................................................111

Figure 24: Diagnostic marker candidate to a product ........................................................................................................................................................................ 111Association studies/clinical data ......................................................................................................................................112

Figure 25: Biomarkers distinguish Leukaemia subclasses ................................................................................................................................................................. 112Management strategy ......................................................................................................................................................112Application & market potential .......................................................................................................................................113Biomarker analysis ............................................................................................................................................................113

SuperArray Bioscience Corporation .................................................................................................................................. 114Biomarker novelty & technology platform .....................................................................................................................114Association studies/clinical data ......................................................................................................................................114Management strategy ......................................................................................................................................................114Application & market potential .......................................................................................................................................114Biomarker analysis ............................................................................................................................................................114

Third Wave Technologies .................................................................................................................................................... 116

©Espicom Business Intelligence ixAugust 2008


Biomarker novelty & technology platform .....................................................................................................................116Association studies/clinical data ......................................................................................................................................116Management strategy ......................................................................................................................................................116Application & market potential .......................................................................................................................................116Biomarker analysis ............................................................................................................................................................117

Upstream Biosciences .......................................................................................................................................................... 118Biomarker novelty & technology platform .....................................................................................................................118Association studies/clinical data ......................................................................................................................................118Management strategy ......................................................................................................................................................118Application & market potential .......................................................................................................................................118Biomarker analysis ............................................................................................................................................................119

Veridex, LLC ........................................................................................................................................................................... 120Biomarker novelty & technology platform .....................................................................................................................120Association studies/clinical data ......................................................................................................................................120Management strategy ......................................................................................................................................................120Application & market potential .......................................................................................................................................121Biomarker analysis ............................................................................................................................................................121

Vermillion ............................................................................................................................................................................... 122Biomarker novelty & technology platform .....................................................................................................................122Association studies/clinical data ......................................................................................................................................122Management strategy ......................................................................................................................................................122Application & market potential .......................................................................................................................................123Biomarker analysis ............................................................................................................................................................123

CANCER BIOMARKER APPENDIX 1 ........................................................................................................... 124Table 8: Global biomarker sales 2007-20015E ...................................................................................................................................................................................124

CANCER BIOMARKER APPENDIX 2 ........................................................................................................... 125Table 8: Global cancer biomarker sales 2007-20015E ........................................................................................................................................................................125

CANCER BIOMARKER APPENDIX 3 ........................................................................................................... 126Company Analysis Criteria .................................................................................................................................................. 126

Biomarker technology & platforms .................................................................................................................................126Association studies ...........................................................................................................................................................126Management strategy .....................................................................................................................................................126Application & potential .....................................................................................................................................................126

Table 9: Key cancer biomarker companies .........................................................................................................................................................................................128Figure 26: Leading Cancer Biomarker Companies – Service providers, Technology Providers, Biomarker Discovery & Diagnostic Developers...............................130

GLOSSARY ..................................................................................................................................................131ACRONYMS ................................................................................................................................................ 133BIBLIOGRAPHY & ENDNOTES ................................................................................................................... 138CNS MARKET & REVENUES ....................................................................................................................... 139

Market revenues - global ..................................................................................................................................................139Figure 1: Global CNS drugs sales (2007) .............................................................................................................................................................................................139

Market revenues – leading brands ................................................................................................................................. 140Figure 2: Leading CNS brands (2007) .................................................................................................................................................................................................140

Market revenues – leading players ..................................................................................................................................141Figure 3: Top 10 CNS players (2007 revenues) ....................................................................................................................................................................................141

CNS EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT ...................................................................................... 142Epidemiology .....................................................................................................................................................................142

Table 1: CNS statistics for the most common CNS disorders, 2008 .....................................................................................................................................................142Diagnosis ............................................................................................................................................................................142

Table 2: Indication for CT and MRI in the CNS .....................................................................................................................................................................................143Screening ...........................................................................................................................................................................143

©Espicom Business Intelligence August 2008x


Current & future treatment ..............................................................................................................................................143Table 3: Classes of CNS drugs approved for acute and chronic conditions .........................................................................................................................................144

Future treatment .............................................................................................................................................................. 144Figure 4: CNS drugs in clinical development .......................................................................................................................................................................................144

CNS BIOMARKERS ................................................................................................................................................................145CNS biomarker R&D ...........................................................................................................................................................145

Figure 5: Imaging biomarkers as surrogate endpoints ......................................................................................................................................................................146Table 4: Types of biomarker ................................................................................................................................................................................................................146

Known CNS biomarkers ....................................................................................................................................................147Table 5: Commercially available known CNS biomarker diagnostics ................................................................................................................................................147

Probable and possible valid CNS biomarkers .................................................................................................................147Table 6: Probable CNS biomarkers diagnostics .................................................................................................................................................................................148Table 7: Possible CNS biomarkers diagnostics ...................................................................................................................................................................................148

CNS BIOMARKER OPPORTUNITIES & CHALLENGES ........................................................................................................ 152Opportunities ....................................................................................................................................................................152

Figure 7: CNS biomarker opportunities .............................................................................................................................................................................................152Challenges ..........................................................................................................................................................................153

Figure 8: CNS biomarker challenges ..................................................................................................................................................................................................153BIOMARKER MARKET ........................................................................................................................................................... 155

Biomarker market revenues - global ...............................................................................................................................155Figure 9: Global biomarker sales in 2007 ...........................................................................................................................................................................................155

CNS biomarker market revenues - global .......................................................................................................................156Figure 10: Global CNS biomarker sales in 2007 ..................................................................................................................................................................................156

Future biomarker market revenues – global ..................................................................................................................156Figure 11: Global biomarker sales in 2015 ..........................................................................................................................................................................................157

Future CNS biomarker market revenues - global ...........................................................................................................157Figure 12: Global CNS biomarker sales in 2015 ..................................................................................................................................................................................158

CNS BIOMARKER TRENDS .................................................................................................................................................... 159Table 8: Recent deals in the oncology biomarkers .............................................................................................................................................................................159

Pharma deals .................................................................................................................................................................... 160Collaborations with CNS discovery companies ............................................................................................................. 160Collaborations with academics and consortia .............................................................................................................. 160

BIOMARKER ANALYSIS .........................................................................................................................................................162DNA biomarkers ............................................................................................................................................................... 162Proteomic biomarkers ..................................................................................................................................................... 162Metabolomic biomarkers ................................................................................................................................................ 162Electrophysiology biomarkers ........................................................................................................................................ 162Imaging biomarkers ......................................................................................................................................................... 162

KEY BIOMARKER COMPANIES ANALYSED .........................................................................................................................163KEY BIOMARKER EVALUATION CRITERIA ..........................................................................................................................164

CNS BIOMARKER- COMPANY ANALYSIS .................................................................................................. 165Affymetrix ..............................................................................................................................................................................165

Biomarker novelty & technology platform .................................................................................................................... 165Association studies/clinical data ..................................................................................................................................... 165Management strategy ..................................................................................................................................................... 165Application & market potential ...................................................................................................................................... 166Biomarker analysis ........................................................................................................................................................... 166

Applied NeuroSolutions ..................................................................................................................................................... 167Biomarker novelty & technology platform .....................................................................................................................167Association studies/clinical data ......................................................................................................................................167Management strategy ......................................................................................................................................................167

©Espicom Business Intelligence xiAugust 2008


Application & market potential .......................................................................................................................................167Biomarker analysis ........................................................................................................................................................... 168

Banyan Biomarkers ..............................................................................................................................................................169Biomarker novelty & technology platform .................................................................................................................... 169

Figure 14: Source Of Banyans TNI biomarkers ...................................................................................................................................................................................169Association studies/clinical data ..................................................................................................................................... 169Management strategy ..................................................................................................................................................... 169Application & market potential ...................................................................................................................................... 169Biomarker analysis ............................................................................................................................................................170

BG Medicine ........................................................................................................................................................................... 171Biomarker novelty & technology platform .....................................................................................................................171Association studies/clinical data ......................................................................................................................................171Management strategy ......................................................................................................................................................171Application & market potential .......................................................................................................................................172Biomarker analysis ............................................................................................................................................................172

Biosite, Inc .............................................................................................................................................................................. 173Biomarker novelty & technology platform .....................................................................................................................173Association studies/clinical data ......................................................................................................................................173Management strategy ......................................................................................................................................................173Application & market potential .......................................................................................................................................174Biomarker analysis ............................................................................................................................................................174

Biospective ............................................................................................................................................................................. 175Biomarker novelty & technology platform .....................................................................................................................175Association studies/clinical data ......................................................................................................................................175Management strategy ......................................................................................................................................................175Application & market potential .......................................................................................................................................175Biomarker analysis ............................................................................................................................................................176

Celera, Inc ............................................................................................................................................................................... 177Biomarker novelty & technology platform .....................................................................................................................177Association studies/clinical data ......................................................................................................................................177Management strategy ......................................................................................................................................................177Application & market potential .......................................................................................................................................177Biomarker analysis ............................................................................................................................................................178

Clinical Data Inc ..................................................................................................................................................................... 179Biomarker novelty & technology platform .....................................................................................................................179Association studies/clinical data ......................................................................................................................................179Management strategy ..................................................................................................................................................... 180Application & market potential ...................................................................................................................................... 180Biomarker analysis ........................................................................................................................................................... 180

Curidium Medica ................................................................................................................................................................... 181Biomarker novelty & technology platform .....................................................................................................................181Association studies/clinical data ......................................................................................................................................181

Figure 17: Curidium’s PsychINDx test for schizophrenia/bipolar disorder ..........................................................................................................................................181Management strategy ..................................................................................................................................................... 182Application & market potential ...................................................................................................................................... 182

Digilab Peptidomics .............................................................................................................................................................183Biomarker novelty & technology platform .................................................................................................................... 183Association studies/clinical data ..................................................................................................................................... 183Management strategy ..................................................................................................................................................... 183Application & market potential ...................................................................................................................................... 183Biomarker analysis ........................................................................................................................................................... 184

©Espicom Business Intelligence August 2008xii


EnVivo Pharmaceuticals ......................................................................................................................................................185Biomarker novelty & technology platform .................................................................................................................... 185Association studies/clinical data ..................................................................................................................................... 185Management strategy ..................................................................................................................................................... 185Application & market potential ...................................................................................................................................... 185Biomarker analysis ........................................................................................................................................................... 186

Innogenetics NV ....................................................................................................................................................................187Biomarker novelty & technology platform .................................................................................................................... 187

Figure 18: Innogenetic multiparameter analysis ...............................................................................................................................................................................187Association studies/clinical data ..................................................................................................................................... 187Management strategy ..................................................................................................................................................... 187Application & market potential ...................................................................................................................................... 188Biomarker analysis ........................................................................................................................................................... 188

KineMed, Inc ..........................................................................................................................................................................189Biomarker novelty & technology platform .................................................................................................................... 189

Figure 19: KineMarker technology platform ......................................................................................................................................................................................189Association studies/clinical data ..................................................................................................................................... 190Management strategy ..................................................................................................................................................... 190Application & market potential ...................................................................................................................................... 190Biomarker analysis ........................................................................................................................................................... 190

Lipomics Technologies ........................................................................................................................................................ 191Biomarker novelty & technology platform .....................................................................................................................191Association studies/clinical data ......................................................................................................................................191Management strategy ......................................................................................................................................................191Application & market potential .......................................................................................................................................191Biomarker analysis ............................................................................................................................................................192

Luminex Corporation ........................................................................................................................................................... 193Biomarker novelty & technology platform .....................................................................................................................193Association studies/clinical data ......................................................................................................................................193Management strategy ......................................................................................................................................................193

Figure 20: Luminex is capturing end-user market share ...................................................................................................................................................................194Application & market potential ...................................................................................................................................... 194Biomarker analysis ........................................................................................................................................................... 194

Memory Pharmaceuticals Corporation ............................................................................................................................195Biomarker novelty & technology platform .................................................................................................................... 195Association studies/clinical data ..................................................................................................................................... 195Management strategy ..................................................................................................................................................... 195Application & market potential ...................................................................................................................................... 195Biomarker analysis ........................................................................................................................................................... 196

Metabolon, Inc ...................................................................................................................................................................... 197Biomarker novelty & technology platform .....................................................................................................................197

Figure 21: Metabolon integrated analytic platform ..........................................................................................................................................................................197Association studies/clinical data ......................................................................................................................................197Management strategy ..................................................................................................................................................... 198Application & market potential ...................................................................................................................................... 198Biomarker analysis ........................................................................................................................................................... 198

Nanogen, Inc .........................................................................................................................................................................199Biomarker novelty & technology platform .................................................................................................................... 199Association studies/clinical data ..................................................................................................................................... 199Management strategy ..................................................................................................................................................... 199Application & market potential ...................................................................................................................................... 199

©Espicom Business Intelligence xiiiAugust 2008


Biomarker analysis ........................................................................................................................................................... 200Nanosphere, Inc. ...................................................................................................................................................................201

Biomarker novelty & technology platform .................................................................................................................... 201Figure 22. Nanosphere’s gold nanoparticle technology ....................................................................................................................................................................201

Association studies/clinical data ..................................................................................................................................... 202Management strategy ..................................................................................................................................................... 202Application & market potential ...................................................................................................................................... 202Biomarker analysis ........................................................................................................................................................... 202

Nymox Pharmaceutical .......................................................................................................................................................203Biomarker novelty & technology platform .................................................................................................................... 203Association studies/clinical data ..................................................................................................................................... 203Management strategy ..................................................................................................................................................... 203Application & market potential ...................................................................................................................................... 203Biomarker analysis ........................................................................................................................................................... 204

Competitor Ratio Analysis Score = 12/40 ..........................................................................................................................................................................................204Osta Biotechnologies ...........................................................................................................................................................205


Phenomenome Discoveries, Inc .........................................................................................................................................207Biomarker novelty & technology platform .................................................................................................................... 207Association studies/clinical data ..................................................................................................................................... 207Management strategy ..................................................................................................................................................... 207Application & market potential ...................................................................................................................................... 207Biomarker analysis ........................................................................................................................................................... 208

PPD, Inc ...................................................................................................................................................................................209Biomarker novelty & technology platform .................................................................................................................... 209Association studies/clinical data ..................................................................................................................................... 209Management strategy ..................................................................................................................................................... 209Application & market potential ...................................................................................................................................... 209Biomarker analysis ............................................................................................................................................................210

Competitor Ratio Analysis Score = 16/40 ..........................................................................................................................................................................................210Power3 Medical Products .................................................................................................................................................... 211


Provista Life Sciences ........................................................................................................................................................... 213Biomarker novelty & technology platform .....................................................................................................................213Association studies/clinical data ......................................................................................................................................213Management strategy ......................................................................................................................................................213Application & market potential .......................................................................................................................................213Biomarker analysis ............................................................................................................................................................214

Psynova Neurotech Ltd........................................................................................................................................................ 215Biomarker novelty & technology platform .....................................................................................................................215Association studies/clinical data ......................................................................................................................................215

Figure 23: Two proteins identified in CSF are also biomarkers in serum ............................................................................................................................................ 215Management strategy ......................................................................................................................................................216

©Espicom Business Intelligence August 2008xiv


Application & market potential .......................................................................................................................................216Biomarker analysis ............................................................................................................................................................216

Satoris, Inc .............................................................................................................................................................................. 217Biomarker novelty & technology platform .....................................................................................................................217Association studies/clinical data ......................................................................................................................................217

Figure 24: Early identification of Alzheimer's disease in at-risk MCI patients ....................................................................................................................................217Management strategy ......................................................................................................................................................218Application & market potential .......................................................................................................................................218Biomarker analysis ............................................................................................................................................................218

Siemens Medical Solutions ................................................................................................................................................. 219Biomarker novelty & technology platform .....................................................................................................................219

Figure 25: Siemens Integrated in vivo & in vitro diagnostic suites .....................................................................................................................................................219Association studies/clinical data ......................................................................................................................................219Management strategy ..................................................................................................................................................... 220Application & market potential ...................................................................................................................................... 220Biomarker analysis ........................................................................................................................................................... 220

Competitor Ratio Analysis Score = 20/40 ..........................................................................................................................................................................................220SuperArray Bioscience Corporation ..................................................................................................................................222


CNS BIOMARKER APPENDIX 1 .................................................................................................................. 224Table 9: Global biomarker sales 2007-20015E ...................................................................................................................................................................................224

CNS BIOMARKER APPENDIX 2 .................................................................................................................. 225Table 10: Global CNS biomarker sales 2007-20015E ..........................................................................................................................................................................225

CNS BIOMARKER APPENDIX 3 .................................................................................................................. 226Company Analysis Criteria ..................................................................................................................................................226

Biomarker technology & platforms ................................................................................................................................ 226Association studies .......................................................................................................................................................... 226Management strategy .................................................................................................................................................... 226Application & potential .................................................................................................................................................... 226

Table 9: Key CNS Biomarker Companies .............................................................................................................................................................................................227Figure 26: Leading CNS Biomarker Companies – Service Providers, Technology Providers, Biomarker Discovery & Diagnostic Developers ...................................228

GLOSSARY ................................................................................................................................................. 229ACRONYMS ................................................................................................................................................ 234BIBLIOGRAPHY ......................................................................................................................................... 239CARDIOVASCULAR MARKET & REVENUES .............................................................................................. 241

Market revenues - global ..................................................................................................................................................241Figure 1: Global cardiovascular disease drug sales 2007 ..................................................................................................................................................................241

Market revenues – leading brands ................................................................................................................................. 242Figure 2: Leading Cardiovascular brands (2007) ...............................................................................................................................................................................242

Market revenues – leading players ................................................................................................................................. 243Figure 3: Top 10 cardiovascular players (2007 revenues) ..................................................................................................................................................................243

CARDIOVASCULAR EPIDEMIOLOGY, DIAGNOSIS, SCREENING & TREATMENT ...........................................................244Epidemiology .................................................................................................................................................................... 244

Figure 4: Breakdown of deaths from cardiovascular diseases in the US (2004) ................................................................................................................................245Diagnosis ........................................................................................................................................................................... 245Screening .......................................................................................................................................................................... 246

Table 1: Screening for cardiovascular disease ....................................................................................................................................................................................246

©Espicom Business Intelligence xvAugust 2008


Current treatments .......................................................................................................................................................... 246Table 2: Cardiovascular therapeutic drug categories and their indications .......................................................................................................................................247

Future treatments ............................................................................................................................................................ 247Figure 5: Drugs in clinical development for heart disease ..................................................................................................................................................................248

CARDIOVASCULAR BIOMARKERS ......................................................................................................................................249Cardiovascular biomarker R&D ....................................................................................................................................... 249

Figure 6: Impact of biomarkers on the drug R&D process ..................................................................................................................................................................250Table 3: Types of biomarker ................................................................................................................................................................................................................251

Known cardiovascular biomarkers ................................................................................................................................. 251Table 4: Commercially available cardiovascular diagnostics .............................................................................................................................................................251

Probable and possible valid cardiovascular biomarkers .............................................................................................. 253Table 5: Probable cardiovascular biomarkers ...................................................................................................................................................................................254Table 6: Possible cardiovascular biomarkers .....................................................................................................................................................................................255

CARDIOVASCULAR BIOMARKER OPPORTUNITIES & CHALLENGES ..............................................................................258Opportunities ................................................................................................................................................................... 258

Figure 7: Cardiovascular biomarker opportunities ............................................................................................................................................................................258Challenges ......................................................................................................................................................................... 259

Figure 8: Cardiovascular biomarker challenges ................................................................................................................................................................................259BIOMARKER MARKET ...........................................................................................................................................................261

Biomarker market revenues – global ..............................................................................................................................261Figure 9: Global biomarker sales in 2007 ...........................................................................................................................................................................................261

Cardiovascular biomarker market revenues – global .................................................................................................. 262Figure 10: Global cardiovascular biomarker sales in 2007 ................................................................................................................................................................262

Future biomarker market revenues – global ................................................................................................................. 262Figure 11: Global biomarker sales in 2015 ..........................................................................................................................................................................................263

Future cardiovascular biomarker market revenues – global ....................................................................................... 263Figure 12: Global cardiovascular biomarker sales in 2015 .................................................................................................................................................................263

CARDIOVASCULAR BIOMARKER TRENDS .........................................................................................................................264Table 7: Recent deals in cardiovascular biomarkers ...........................................................................................................................................................................264

Pharma and specialty pharma deals .............................................................................................................................. 265Collaborations with service providers ........................................................................................................................... 265Collaborations with academics and consortia .............................................................................................................. 265

BIOMARKER ANALYSIS .........................................................................................................................................................266Assays for circulating biomarkers ................................................................................................................................... 266DNA and RNA biomarkers ................................................................................................................................................ 266Proteomic, metabolomic biomarkers ............................................................................................................................ 266Systems biology for biomarker discovery ...................................................................................................................... 266Imaging biomarkers ......................................................................................................................................................... 267

KEY BIOMARKER COMPANIES ANALYSED .........................................................................................................................268KEY BIOMARKER EVALUATION CRITERIA ..........................................................................................................................269

CARDIOVASCULAR BIOMARKERS - COMPANY ANALYSIS ....................................................................... 270Abbott Diagnostics ..............................................................................................................................................................270


Atherotech .............................................................................................................................................................................272Biomarker novelty & technology platform .................................................................................................................... 272Association studies/clinical data ..................................................................................................................................... 272Management strategy ..................................................................................................................................................... 272

©Espicom Business Intelligence August 2008xvi


Application & market potential ...................................................................................................................................... 272Biomarker analysis ........................................................................................................................................................... 272

Affymetrix ..............................................................................................................................................................................273Biomarker novelty & technology platform .................................................................................................................... 273

Figure 13: Affymetrix’ approach to biomarker discovery, validation and clinical utility applications ...............................................................................................273Association studies/clinical data ..................................................................................................................................... 273Management strategy ......................................................................................................................................................274Application & market potential .......................................................................................................................................274Biomarker analysis ............................................................................................................................................................275

Beckman Coulter ..................................................................................................................................................................276Biomarker novelty & technology platform .....................................................................................................................276Association studies/clinical data ......................................................................................................................................276Management strategy ......................................................................................................................................................276Application & market potential ...................................................................................................................................... 277Biomarker analysis ........................................................................................................................................................... 277

Berkeley HeartLab ................................................................................................................................................................278Biomarker novelty & technology platform .................................................................................................................... 278

Figure 14: Markers of cardiovascular disease measured at Berkeley HeartLab .................................................................................................................................278Association studies/clinical data ..................................................................................................................................... 278Management strategy ..................................................................................................................................................... 279Application & market potential ...................................................................................................................................... 279Biomarker analysis ........................................................................................................................................................... 279

BG Medicine ..........................................................................................................................................................................280Biomarker novelty & technology platform .................................................................................................................... 280Association studies/clinical data ..................................................................................................................................... 280Management strategy ..................................................................................................................................................... 280

Figure 15: BG Medicine’s Biomarker Programme ..............................................................................................................................................................................281Application & market potential ...................................................................................................................................... 281Biomarker analysis ........................................................................................................................................................... 282

CardioDx .................................................................................................................................................................................283Biomarker novelty & technology platform .................................................................................................................... 283Association studies/clinical data ..................................................................................................................................... 283Management strategy ..................................................................................................................................................... 283Application & market potential ...................................................................................................................................... 283Biomarker analysis ........................................................................................................................................................... 284

Competitor Ratio Analysis Score = 9/40 ............................................................................................................................................................................................284Celera ......................................................................................................................................................................................285


CIS Biotech .............................................................................................................................................................................287Biomarker novelty & technology platform .................................................................................................................... 287Association studies/clinical data ..................................................................................................................................... 287Management strategy ..................................................................................................................................................... 287Application & market potential ...................................................................................................................................... 287Biomarker analysis ........................................................................................................................................................... 288

Clinical Data ...........................................................................................................................................................................289Biomarker novelty & technology platform .................................................................................................................... 289Association studies/clinical data ..................................................................................................................................... 289

©Espicom Business Intelligence xviiAugust 2008


Management strategy ..................................................................................................................................................... 290Application & market potential ...................................................................................................................................... 290Biomarker analysis ........................................................................................................................................................... 290

Compugen .............................................................................................................................................................................291Biomarker novelty & technology platform .................................................................................................................... 291Association studies/clinical data ..................................................................................................................................... 291Management strategy ..................................................................................................................................................... 291Application & market potential ...................................................................................................................................... 292Biomarker analysis ........................................................................................................................................................... 292

Critical Diagnostics ...............................................................................................................................................................293Biomarker novelty & technology platform .................................................................................................................... 293Association studies/clinical data ..................................................................................................................................... 293Management strategy ..................................................................................................................................................... 293Application & market potential ...................................................................................................................................... 293Biomarker analysis ........................................................................................................................................................... 294

deCODE Genetics ..................................................................................................................................................................295Biomarker novelty & technology platform .................................................................................................................... 295Association studies/clinical data ..................................................................................................................................... 295Management strategy ..................................................................................................................................................... 295

Figure 16: deCODE’s approach to target discovery and development ................................................................................................................................................296Application & market potential ...................................................................................................................................... 296Biomarker analysis ........................................................................................................................................................... 296

diaDexus .................................................................................................................................................................................297Biomarker novelty & technology platform .................................................................................................................... 297Association studies/clinical data ..................................................................................................................................... 297Management strategy ..................................................................................................................................................... 297Application & market potential ...................................................................................................................................... 297Biomarker analysis ........................................................................................................................................................... 298

Entelos ....................................................................................................................................................................................299Biomarker novelty & technology platform .................................................................................................................... 299Association studies/clinical data ..................................................................................................................................... 299Management strategy ..................................................................................................................................................... 299Application & market potential ...................................................................................................................................... 299Biomarker analysis ........................................................................................................................................................... 300

FoxHollow Technologies ....................................................................................................................................................301Biomarker novelty & technology platform .................................................................................................................... 301Association studies/clinical data ..................................................................................................................................... 301Management strategy ..................................................................................................................................................... 301Application & market potential ...................................................................................................................................... 301Biomarker analysis ........................................................................................................................................................... 302

GE Healthcare ........................................................................................................................................................................303Biomarker novelty & technology platform .................................................................................................................... 303

Figure 17: Cardiology focus at GE Healthcare ....................................................................................................................................................................................303Association studies/clinical data ..................................................................................................................................... 304Management strategy ..................................................................................................................................................... 304Application & market potential ...................................................................................................................................... 304Biomarker analysis ........................................................................................................................................................... 304

Genomas ...............................................................................................................................................................................305Biomarker novelty & technology platform .................................................................................................................... 305

Figure 18: PhysioGenomics Technology from Genomas ....................................................................................................................................................................305Association studies/clinical data ..................................................................................................................................... 305

©Espicom Business Intelligence August 2008xviii



Inverness Medical Innovations ...........................................................................................................................................307Biomarker novelty & technology platform .................................................................................................................... 307Association studies/clinical data ..................................................................................................................................... 307Management strategy ..................................................................................................................................................... 307Application & market potential ...................................................................................................................................... 308Biomarker analysis ........................................................................................................................................................... 308

Jurilab .....................................................................................................................................................................................309Biomarker novelty & technology platform .................................................................................................................... 309

Figure 19: Jurilab’s Genetic Discovery Method ...................................................................................................................................................................................310Association studies/clinical data ......................................................................................................................................310Management strategy ......................................................................................................................................................311Application & market potential .......................................................................................................................................311Biomarker analysis ............................................................................................................................................................311

Competitor Ratio Analysis Score = 12/40 .......................................................................................................................................................................................... 311Laboratory Corporation of America .................................................................................................................................. 312


Lipomics Technologies ........................................................................................................................................................ 314Biomarker novelty & technology platform .....................................................................................................................314Association studies/clinical data ......................................................................................................................................314Management strategy ......................................................................................................................................................314Application & market potential .......................................................................................................................................314Biomarker analysis ............................................................................................................................................................315

LipoScience ............................................................................................................................................................................ 316Biomarker novelty & technology platform .....................................................................................................................316Association studies/clinical data ......................................................................................................................................316Management strategy ......................................................................................................................................................316Application & market potential .......................................................................................................................................316Biomarker analysis ............................................................................................................................................................317

Competitor Ratio Analysis Score = 15/40 .......................................................................................................................................................................................... 317Nanosphere Inc. .................................................................................................................................................................... 318


Osmetech Molecular Diagnostics ......................................................................................................................................320Biomarker novelty & technology platform .................................................................................................................... 320Association studies/clinical data ..................................................................................................................................... 320Management strategy ..................................................................................................................................................... 320Application & market potential ...................................................................................................................................... 320Biomarker analysis ............................................................................................................................................................321

Competitor Ratio Analysis Score = 12/40 ..........................................................................................................................................................................................321PrognostiX .............................................................................................................................................................................322

Biomarker novelty & technology platform .................................................................................................................... 322

©Espicom Business Intelligence xixAugust 2008


Association studies/clinical data ..................................................................................................................................... 322Management strategy ..................................................................................................................................................... 322Application & market potential ...................................................................................................................................... 322Biomarker analysis ........................................................................................................................................................... 322

Quest Diagnostics .................................................................................................................................................................323Biomarker novelty & technology platform .................................................................................................................... 323Association studies/clinical data ..................................................................................................................................... 323Management strategy ..................................................................................................................................................... 323Application & market potential ...................................................................................................................................... 323Biomarker analysis ........................................................................................................................................................... 324

Competitor Ratio Analysis Score = 27/40 ..........................................................................................................................................................................................324Roche Diagnostics ................................................................................................................................................................325

Biomarker novelty & technology platform .................................................................................................................... 325Figure 20: Roche’s technologies for biomarker discovery and development .....................................................................................................................................325

Association studies/clinical data ..................................................................................................................................... 325Figure 21: Roche’s clinical trial programme for cardiac biomarker NT-proBNP .................................................................................................................................326


Siemens Medical Solutions .................................................................................................................................................328Biomarker novelty & technology platform .................................................................................................................... 328

Figure 22: Siemens Integrated in vivo & in vitro diagnostic suites .....................................................................................................................................................328Association studies/clinical data ..................................................................................................................................... 328Management strategy ..................................................................................................................................................... 329Application & market potential ...................................................................................................................................... 329Biomarker analysis ........................................................................................................................................................... 329

Singulex ..................................................................................................................................................................................330Biomarker novelty & technology platform .................................................................................................................... 330

Figure 23: Sensitivity of Singulex’s Erenna system compared to ELISA and bead-based fluorescence readout systems ...................................................................330Association studies/clinical data ..................................................................................................................................... 330Management strategy ......................................................................................................................................................331Application & market potential .......................................................................................................................................331Biomarker analysis ............................................................................................................................................................331

SuperArray Bioscience Corporation ..................................................................................................................................332Biomarker novelty & technology platform .................................................................................................................... 332Association studies/clinical data ..................................................................................................................................... 332Management strategy ..................................................................................................................................................... 332Application & market potential ...................................................................................................................................... 332Biomarker analysis ........................................................................................................................................................... 333

Vermillion ...............................................................................................................................................................................334Biomarker novelty & technology platform .................................................................................................................... 334Association studies/clinical data ..................................................................................................................................... 334Management strategy ..................................................................................................................................................... 334Application & market potential ...................................................................................................................................... 335Biomarker analysis ........................................................................................................................................................... 335

Zora Biosciences OY ..............................................................................................................................................................336Biomarker novelty & technology platform .................................................................................................................... 336

Table 8: Zora metabolite profiling platform .......................................................................................................................................................................................336Association studies/clinical data ..................................................................................................................................... 336Management strategy ..................................................................................................................................................... 336Application & market potential ...................................................................................................................................... 336

©Espicom Business Intelligence August 2008xx


Biomarker analysis ........................................................................................................................................................... 337CARDIOVASCULAR BIOMARKER APPENDIX 1 ......................................................................................... 338

Table 9: Global biomarker sales 2007-20015E ...................................................................................................................................................................................338CARDIOVASCULAR BIOMARKER APPENDIX 2 ......................................................................................... 339

Table 10: Global cardiovascular biomarker sales 2007-20015E .........................................................................................................................................................339CARDIOVASCULAR BIOMARKER APPENDIX 3 ......................................................................................... 340

Company Analysis Criteria ..................................................................................................................................................340Biomarker technology & platforms ................................................................................................................................ 340Association studies .......................................................................................................................................................... 340Management strategy .................................................................................................................................................... 340Application & potential .................................................................................................................................................... 340

Table 9: Key cardiovascular biomarker companies ............................................................................................................................................................................341Figure 26: Leading Cardiovascular Biomarker Companies – Service providers, Technology Providers, Biomarker Discovery & Diagnostic Developers .................343

GLOSSARY ................................................................................................................................................. 344ACRONYMS ................................................................................................................................................ 346BIBLIOGRAPHY & ENDNOTES ................................................................................................................... 350

Documents

Cancer, CNS & Cardiovascular Biomarkers · Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects. ii ©Espicom Business Intelligence August 2008 Cancer, CNS & Cardiovascular